Evidence-Based Diabetes Management
Evidence-Based Immunology and Infectious Disease
Evidence-Based Respiratory Care
Subscribe for FREE
CML Channel: Chronic Myelogenous Leukemia
AJMC Live Meeting - Oncology
AMCP Spring 2014
NAMCP Spring 2014
Information for AJMC
Information for AJPB
Call for Papers
Submit / Track a Manuscript
Information for Reviewers
Acute Coronary Syndrome
Mantle Cell Lymphoma
Value-Based Insurance Design
Medical Homes and Cost and Utilization Among High-Risk Patients | Page 3
March 24, 2014
Susannah Higgins, MS; Ravi Chawla, MBA; Christine Colombo, MBA; Richard Snyder, MD; and Somesh Nigam, PhD
PDF is available on the last page.
<< Previous Page (Page 2)
Issue: March 2014
STABLE Results: Warfarin Home Monitoring Achieves Excellent INR Control
Grace DeSantis, PhD; Jackie Hogan-Schlientz, RN, BSN; Gary Liska, BS; Shari Kipp, BS; Ramarion Sallee; Mark Wurster, MD; Kenneth Kupfer, PhD; and Jack Ansell, MD
Real-world retrospective analysis of over 29,000 patients performing INR home monitoring for warfarin therapy shows excellent time in therapeutic range.
Do Strict Formularies Replicate Failure for Patients With Schizophrenia?
Dana P. Goldman, PhD; Riad Dirani, PhD; John Fastenau, MPH, RPh; and Ryan M. Conrad, PhD
This study measures the impact of Medicaid formulary restrictions on the rate at which patients who failed on a drug therapy for schizophrenia return to the same therapy.
The Economics of Resistant Pathogens and Antibiotic Innovation
Michael R. McKellar, BA; Michael E. Chernew, PhD; and A. Mark Fendrick, MD
This commentary discusses why antibiotics and the treatment of infectious diseases present a special case for pharmaceutical development, pricing, and appropriate utilization.
Click for Full Issue
More on AJMC.COM
Do Protections Against Genetic Discrimination in Health Coverage Go Far Enough?
Participating Faculty: Standards of Care Issues With Anticoagulation in Real-World Populations
Standards of Care Issues With Anticoagulation in Real-World Populations
Pharma Expects Push-Back on Cancer Drug Costs
HHS Cheers as ACA Sign-Ups Pass 9 Million Mark, but Here’s the Catch: 6.2 Million Could Lose Subsidies in Court Case
Terms & Conditions
| Copyright HCPLive 2006-2014 | Intellisphere, LLC. All Rights Reserved.
Specialty Pharmacy Times